FDA to alter biosimilar ‘suffix’ policy

The US Food and Drug Administration (FDA) yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Senior four-partner team leaves A&O Shearman

16 January 2026 The team, known for pharmaceutical and biotechnology patent litigation—including Hatch-Waxman and BPCIA disputes—as well as trade secret and licensing matters, joins a rival US firm.

Europe

Final call: Who are the world’s best in-house counsel?

16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

Americas

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

15 January 2026 The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.

More features

Senior four-partner team leaves A&O Shearman

Final call: Who are the world’s best in-house counsel?

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Italian medtech startup beats larger US rival in UPC dispute

Senior USPTO solicitor steps into private practice

Goodwin targets transatlantic patent work with London hire

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

FDA to alter biosimilar ‘suffix’ policy

More on this story

Editor's picks

Editor's picks

More features